{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:40:47Z","timestamp":1783996847133,"version":"3.55.0"},"reference-count":165,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Controlled human infection studies offer a unique opportunity to study the efficacy of novel interventions, mechanisms of infection and disease, as well as determine correlates of protection that may underpin the development of novel interventions. Controlled human malaria infection (CHMI) studies supported the clinical development of the first malaria vaccines (i.e. RTSS\/AS01 and R21\/Matrix-M). The CHMI model accurately predicted efficacy of these vaccines and accelerated their clinical development. In addition to vaccine development, over the last decade CHMI studies have supported the advancement of drugs, monoclonal antibodies (mAbs) and been instrumental in characterising immunity to malaria by unravelling immunological and innate mechanisms that may mediate protection. Here, we briefly review the history and rationale of the available falciparum malaria CHMI models. We highlight key applications and lessons learned from CHMI studies conducted in na\u00efve and endemic populations with respect to immunological advances, discoveries in therapeutic targets such as mAbs, and transferring of the models from high income to low- and middle-income settings.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1672945","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T05:32:55Z","timestamp":1758173575000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Controlled human malaria infection studies: insights into recent advances and key immunological and ethical implementation lessons"],"prefix":"10.3389","volume":"16","author":[{"given":"Rodney","family":"Ogwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Adan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bejon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa C.","family":"Kapulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"B1","volume-title":"World malaria report 2023","year":"2023"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17050","DOI":"10.1038\/nrdp.2017.50","article-title":"Malaria","volume":"3","author":"Phillips","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B3","volume-title":"World malaria report 2024","year":"2024"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1101\/2024.03.15.24304352","article-title":"Dramatic resurgence of malaria after 7 years of intensive vector control interventions in Eastern Uganda","author":"Kamya","year":"2024","journal-title":"medRxiv"},{"key":"B5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0140-6736(24)00194-6","article-title":"Routine malaria vaccinations begin","volume":"403","author":"Adepoju","year":"2024","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0140-6736(24)00235-6","article-title":"Malaria vaccines: a test for global health","volume":"403","author":"The","year":"2024","journal-title":"Lancet"},{"key":"B7","article-title":"Malaria vaccine: WHO position paper \u20132024 \u2013","volume":"99","year":"2024","journal-title":"Weekly Epidemiological"},{"key":"B8","volume-title":"Global technical strategy for malaria 2016-2030","year":"2015"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002380","article-title":"Tools and strategies for malaria control and elimination: what do we need to achieve a grand convergence in malaria","volume":"14","author":"Hemingway","year":"2016","journal-title":"PloS Biol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.paed.2024.12.002","article-title":"Effective vaccination for malaria and wider implications for future global child health","volume":"35","author":"Ogwang","year":"2025","journal-title":"Paediatrics Child Health"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00008-21","article-title":"Controlled human infection models to accelerate vaccine development","volume":"35","author":"Choy","year":"2022","journal-title":"Clin Microbiol Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805832","article-title":"Protection against a malaria challenge by sporozoite inoculation","volume":"361","author":"Roestenberg","year":"2009","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.06.009","article-title":"Use of controlled human infection models (CHIMs) to support vaccine development: US regulatory considerations","volume":"37","author":"Ramanathan","year":"2019","journal-title":"Vaccine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw145","article-title":"Single-dose live oral cholera vaccine CVD 103-hgR protects against human experimental infection withVibrio choleraeO1 El Tor","volume":"62","author":"Chen","year":"2016","journal-title":"Clin Infect Diseases"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2005.11928028","article-title":"Edward Jenner and the history of smallpox and vaccination","volume":"18","author":"Riedel","year":"2005","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw237","article-title":"Fractional third and fourth dose of RTS,S\/AS01 malaria candidate vaccine: A phase 2a controlled human malaria parasite infection and immunogenicity study","volume":"214","author":"Regules","year":"2016","journal-title":"J Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"100867","DOI":"10.1016\/S2666-5247(24)00083-1","article-title":"R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18\u201345 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study","volume":"6","author":"Venkatraman","year":"2025","journal-title":"Lancet Microbe"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir770","article-title":"Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of plasmodium falciparum malaria in a human challenge model","volume":"54","author":"Deye","year":"2012","journal-title":"Clin Infect Diseases"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw174","article-title":"Efficacy of OZ439 (artefenomel) against earlyPlasmodium falciparumblood-stage malaria infection in healthy volunteers","volume":"71","author":"McCarthy","year":"2016","journal-title":"J Antimicrobial Chemother"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4512","article-title":"A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite","volume":"24","author":"Kisalu","year":"2018","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","article-title":"A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver","volume":"53","author":"Wang","year":"2020","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz5629","article-title":"A double-blind, placebo-controlled phase 1\/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1","volume":"12","author":"Roestenberg","year":"2020","journal-title":"Sci Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.03582","article-title":"A genetically attenuated malaria vaccine candidate based on P. falciparum b9\/slarp gene-deficient sporozoites","volume":"3","author":"van Schaijk","year":"2014","journal-title":"eLife"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313892","article-title":"Safety and efficacy of immunization with a late-liver-stage attenuated malaria parasite","volume":"391","author":"Lamers","year":"2024","journal-title":"New Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.09.095","article-title":"Novel approaches to whole sporozoite vaccination against malaria","volume":"33","author":"Bijker","year":"2015","journal-title":"Vaccine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"101579","DOI":"10.1016\/j.eclinm.2022.101579","article-title":"PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial","volume":"52","author":"Coulibaly","year":"2022","journal-title":"eClinicalMedicine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03684-z","article-title":"Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity","volume":"595","author":"Mwakingwe-Omari","year":"2021","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/82_2022_256","article-title":"Controlled human malaria infection studies in africa-past, present, and future","volume":"445","author":"Kibwana","year":"2024","journal-title":"Curr Top Microbiol Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2014.00686","article-title":"Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection","volume":"5","author":"Hodgson","year":"2014","journal-title":"Front Microbiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.14-0119","article-title":"Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites","volume":"91","author":"Shekalaghe","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"B32","article-title":"Note sur un nouveau parasite trouv\u00e9 dans le sang de plusieurs malades atteints de fi\u00e8vre palustre","volume":"9","author":"Laveran","year":"1880","journal-title":"Bull Acad Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.1929.1786","article-title":"On some peculiar pigmented cells found in two mosquitos fed on malarial blood","volume":"2","author":"Ross","year":"1897","journal-title":"Br Med J"},{"key":"B34","article-title":"Ulteriore ricerche sul ciclo dei parassiti malarici umani sul corpo del zanzarone (Translated: Further research on the cycle of human malaria parasites on the mosquito body)","volume":"8","author":"Grassi","year":"1899","journal-title":"Atti Reale Accad Lincei"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1756-3305-3-5","article-title":"History of the discovery of the malaria parasites and their vectors","volume":"3","author":"Cox","year":"2010","journal-title":"Parasites Vectors"},{"key":"B36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0035-9203(31)90068-0","article-title":"Some general results of a study of induced malaria in England","volume":"24","author":"James","year":"1931","journal-title":"Trans R Soc Trop Med Hygiene"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2307\/4580870","article-title":"The injection of mosquito sporozoites in malaria therapy","volume":"48","author":"Mayne","year":"1933","journal-title":"Public Health Rep (1896-1970)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/0957154X0001104403","article-title":"Why Wagner-Jauregg won the Nobel Prize for discovering malaria therapy for general paresis of the insane","volume":"11","author":"Brown","year":"2000","journal-title":"History Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.088","article-title":"A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines","volume":"30","author":"Laurens","year":"2012","journal-title":"Vaccine"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.07.049","article-title":"Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18\u201319 March 2009, Bethesda, MD, USA","volume":"27","author":"Moorthy","year":"2009","journal-title":"Vaccine"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2012.10-0658","article-title":"Real-time quantitative reverse transcription PCR for monitoring of blood-stage Plasmodium falciparum infections in malaria human challenge trials","volume":"86","author":"Murphy","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fmala.2025.1497613","article-title":"Quantification of Plasmodium falciparum: validation of quantitative polymerase chain reaction assays for detection of parasites in controlled human malaria infection studies","volume":"3","author":"Kibwana","year":"2025","journal-title":"Front Malaria"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.146443","article-title":"Safety and PCR monitoring in 161 semi-immune Kenyan adults following controlled human malaria infection","volume":"6","author":"Kapulu","year":"2021","journal-title":"JCI Insight"},{"key":"B44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1475-2875-13-38","article-title":"Idiopathic acute myocarditis during treatment for controlled human malaria infection: a case report","volume":"13","author":"van Meer","year":"2014","journal-title":"Malar J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/1475-2875-8-277","article-title":"Cardiac complication after experimental human malaria infection: a case report","volume":"8","author":"Nieman","year":"2009","journal-title":"Malar J"},{"key":"B46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12936-015-0663-x","article-title":"Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines","volume":"14","author":"Stanisic","year":"2015","journal-title":"Malar J"},{"key":"B47","article-title":"Tropical malaria contracted the natural way in the Netherlands","volume":"123","author":"Delemarre","year":"1979","journal-title":"Ned Tijdschr Geneeskd"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis725","article-title":"NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections","volume":"207","author":"Teirlinck","year":"2013","journal-title":"J Infect Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.18-0194","article-title":"Controlled human malaria infection with graded numbers of plasmodium falciparum NF135.C10- or NF166.C8-infected mosquitoes","volume":"99","author":"Langenberg","year":"2018","journal-title":"Am J Trop Med Hygiene"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(74)90129-1","article-title":"Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum","volume":"68","author":"Rieckmann","year":"1974","journal-title":"Trans R Soc Trop Med Hygiene"},{"key":"B51","article-title":"Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria","author":"Rieckmann","year":"1979","journal-title":"Bull World Health Organ"},{"key":"B52","article-title":"A study of monkey-malaria, and its experimental transmission to man","volume":"67","author":"Knowles","year":"1932","journal-title":"Ind Med Gaz"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4269\/ajtmh.2011.09-0498","article-title":"Consistent safety and infectivity in sporozoite challenge model of plasmodium vivax in malaria-naive human volunteers","volume":"84","author":"Herrera","year":"2011","journal-title":"Am J Trop Med Hygiene"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2009.09-0194","article-title":"Successful sporozoite challenge model in human volunteers with plasmodium vivax strain derived from human donors","volume":"81","author":"Herrera","year":"2009","journal-title":"Am J Trop Med Hygiene"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004423","article-title":"Phase 1\/2a trial of plasmodium vivax malaria vaccine candidate VMP001\/AS01B in malaria-naive adults: safety, immunogenicity, and efficacy","volume":"10","author":"Sinnis","year":"2016","journal-title":"PLoS Negl Trop Diseases"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab332","article-title":"Safety and tolerability of mosquito bite-induced controlled human infection with plasmodium vivax in malaria-naive study participants-clinical profile and utility of molecular diagnostic methods","volume":"225","author":"Kamau","year":"2022","journal-title":"J Infect Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz102","article-title":"An experimental human blood-stage model for studying plasmodium malariae infection","volume":"221","author":"Woodford","year":"2019","journal-title":"J Infect Diseases"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.4857.290","article-title":"Protection afforded by sickle-cell trait against subtertian malarial infection","volume":"1","author":"Allison","year":"1954","journal-title":"BMJ"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit394","article-title":"Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers","volume":"208","author":"McCarthy","year":"2013","journal-title":"J Infect Dis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005139","article-title":"Safety and reproducibility of a clinical trial system using induced blood stage plasmodium vivax infection and its potential as a model to evaluate malaria transmission","volume":"10","author":"Sinnis","year":"2016","journal-title":"PLoS Negl Trop Diseases"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.152465","article-title":"Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly","volume":"6","author":"Minassian","year":"2021","journal-title":"JCI Insight"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf1782","article-title":"Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection","volume":"15","author":"Hou","year":"2023","journal-title":"Sci Trans Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1086\/518510","article-title":"Safety and Clinical Outcome of Experimental Challenge of Human Volunteers withPlasmodium falciparum\u2013Infected Mosquitoes: An Update","volume":"196","author":"Epstein Judith","year":"2007","journal-title":"J Infect Diseases"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013490","article-title":"Plasmodium falciparum Malaria Challenge by the Bite of Aseptic Anopheles stephensi Mosquitoes: Results of a Randomized Infectivity Trial","volume":"5","author":"R\u00e9nia","year":"2010","journal-title":"PLoS One"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1086\/339409","article-title":"Protection of Humans against Malaria by Immunization with Radiation-AttenuatedPlasmodium falciparumSporozoites","volume":"185","author":"Hoffman Stephen","year":"2002","journal-title":"J Infect Diseases"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/science.781840","article-title":"Human malaria parasites in continuous culture","volume":"193","author":"Trager","year":"1976","journal-title":"Science"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2307\/3282094","article-title":"Cultivation of Plasmodium falciparum in commercially available sera depleted of natural antibodies reactive with human erythrocytes","volume":"73","author":"Grun","year":"1987","journal-title":"J Parasitol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1986.35.66","article-title":"Malaria transmitted to humans by mosquitoes infected from cultured plasmodium falciparum","volume":"35","author":"Chulay","year":"1986","journal-title":"Am J Trop Med Hygiene"},{"key":"B69","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12936-022-04261-z","article-title":"Efficient infection of non-human primates with purified, cryopreserved Plasmodium knowlesi sporozoites","volume":"21","author":"Chakravarty","year":"2022","journal-title":"Malaria J"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-1014","article-title":"Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults","volume":"99","author":"Jongo","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"B71","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12879-022-07044-8","article-title":"Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response","volume":"22","author":"Kapulu","year":"2022","journal-title":"BMC Infect Dis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00332-7","article-title":"Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial","volume":"22","author":"Sissoko","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-0343","article-title":"Impact of sickle cell trait and naturally acquired immunity on uncomplicated malaria after controlled human malaria infection in adults in Gabon","volume":"98","author":"Lell","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz740","article-title":"Serologic markers of previous malaria exposure and functional antibodies inhibiting parasite growth are associated with parasite kinetics following a plasmodium falciparum controlled human infection","volume":"70","author":"D\u2019Alessandro","year":"2020","journal-title":"Clin Infect Diseases"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.21-0942","article-title":"Multi-dose priming regimens of PfSPZ vaccine: safety and efficacy against controlled human malaria infection in equatoGuinean adults","volume":"106","author":"Jongo","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(67)90005-3","article-title":"Studies on an East African strain of Plasmodium falciparum*1","volume":"61","author":"Martin","year":"1967","journal-title":"Trans R Soc Trop Med Hygiene"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.3.2.214","article-title":"A quinoline methanol (WR 30090) for treatment of acute malaria","volume":"3","author":"Martin","year":"1973","journal-title":"Antimicrobial Agents Chemother"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021914","article-title":"A pilot randomised trial of induced blood-stage plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs","volume":"6","author":"von Seidlein","year":"2011","journal-title":"PLoS One"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2012.09.001","article-title":"Experimentally induced blood stage malaria infection as a tool for clinical research","volume":"28","author":"Engwerda","year":"2012","journal-title":"Trends Parasitol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu063","article-title":"Controlled human malaria infection","author":"Spring","year":"2014","journal-title":"J Infect Dis"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89154","article-title":"Protection against Plasmodium falciparum malaria by PfSPZ Vaccine","volume":"2","author":"Epstein","year":"2017","journal-title":"JCI Insight"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1006954","article-title":"The challenges of Plasmodium vivax human malaria infection models for vaccine development","volume":"13","author":"Roobsoong","year":"2022","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1126\/science.1241800","article-title":"Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine","volume":"341","author":"Seder","year":"2013","journal-title":"Science"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005070","article-title":"Protective Efficacy of Plasmodium vivax Radiation-Attenuated Sporozoites in Colombian Volunteers: A Randomized Controlled Trial","volume":"10","author":"Ar\u00e9valo-Herrera","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"B85","article-title":"Human immunization with attenuated sporozoites","author":"Rieckmann","year":"1990","journal-title":"Bull World Health Organ"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1615324114","article-title":"Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection","volume":"114","author":"Lyke","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn9709","article-title":"A genetically engineered Plasmodium falciparum parasite vaccine provides protection from controlled human malaria infection","volume":"14","author":"Murphy","year":"2022","journal-title":"Sci Transl Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09784-2","article-title":"Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum","volume":"360","author":"Pombo","year":"2002","journal-title":"Lancet"},{"key":"B89","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1056\/NEJM199701093360202","article-title":"A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group","volume":"336","author":"Stoute","year":"1997","journal-title":"N Engl J Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1086\/600120","article-title":"Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection","volume":"200","author":"Kester","year":"2009","journal-title":"J Infect Dis"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.12.041","article-title":"A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S\/AS02A and MVA-CS","volume":"24","author":"Dunachie","year":"2006","journal-title":"Vaccine"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.02.048","article-title":"Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S\/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research","volume":"26","author":"Kester","year":"2008","journal-title":"Vaccine"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1086\/515657","article-title":"Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine","volume":"178","author":"Stoute","year":"1998","journal-title":"J Infect Diseases"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.06.033","article-title":"Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naive adults","volume":"32","author":"Kester","year":"2014","journal-title":"Vaccine"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.08.020","article-title":"Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720","volume":"23","author":"Walther","year":"2005","journal-title":"Vaccine"},{"key":"B96","article-title":"R21 malaria vaccine is protective against intradermal but not intravenous Plasmodium falciparum sporozoites in a randomized controlled human malaria infection study in Kenyan adults","author":"Kapulu","year":"2025","journal-title":"medRxiv"},{"key":"B97","unstructured":"Phase 1 study with the vaccine candidate plasmodium falciparum malaria protein (FMP012), an E.Coli-expressed cell-traversal protein, administered intramuscularly in healthy malaria-naive adults\n          \n          \n          2012"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/nm881","article-title":"Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans","volume":"9","author":"McConkey","year":"2003","journal-title":"Nat Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu579","article-title":"Evaluation of the efficacy of chAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals","volume":"211","author":"Hodgson","year":"2015","journal-title":"J Infect Diseases"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.08.046","article-title":"Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-\u03b3\/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection","volume":"28","author":"Cummings","year":"2010","journal-title":"Vaccine"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.07.067","article-title":"Randomized double-blind controlled Phase I\/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum","volume":"28","author":"Genton","year":"2010","journal-title":"Vaccine"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.223","article-title":"ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans","volume":"20","author":"Sheehy","year":"2012","journal-title":"Mol Ther"},{"key":"B103","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.medj.2021.03.014","article-title":"Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination","volume":"2","author":"Minassian","year":"2021","journal-title":"Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005254","article-title":"Phase 1\/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A","volume":"4","author":"Spring","year":"2009","journal-title":"PloS One"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw039","article-title":"Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1\/AS01","volume":"213","author":"Payne","year":"2016","journal-title":"J Infect Dis"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022271","article-title":"Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1\/alhydrogel+CPG 7909","volume":"6","author":"Gregson","year":"2011","journal-title":"PloS One"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001493","article-title":"Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial","volume":"3","author":"Thompson","year":"2008","journal-title":"PloS One"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0406381102","article-title":"Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara","volume":"102","author":"Webster","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"B109","article-title":"DNA prime\/adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity","volume":"8","author":"Ellis","year":"2013","journal-title":"PloS One"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.4161\/hv.24941","article-title":"Human adenovirus 5-vectoredPlasmodium falciparumNMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection","volume":"9","author":"Tamminga","year":"2014","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw244","article-title":"Safety and high level efficacy of the combination malaria vaccine regimen of RTS,S\/AS01B with chimpanzee adenovirus 63 and modified vaccinia ankara vectored vaccines expressing ME-TRAP","volume":"214","author":"Rampling","year":"2016","journal-title":"J Infect Dis"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00444-2","article-title":"Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers","volume":"18","author":"Lawrence","year":"2000","journal-title":"Vaccine"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1087","article-title":"Controlled human malaria infection of healthy adults with lifelong malaria exposure to assess safety, immunogenicity, and efficacy of the asexual blood stage malaria vaccine candidate GMZ2","volume":"69","author":"Dejon-Agobe","year":"2019","journal-title":"Clin Infect Diseases"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00793-9","article-title":"Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial","volume":"23","author":"Lyke","year":"2023","journal-title":"Lancet Infect Diseases"},{"key":"B115","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJMoa2203067","article-title":"Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria","volume":"387","author":"Wu","year":"2022","journal-title":"New Engl J Med"},{"key":"B116","unstructured":"A phase 1, dose escalation, double blind, placebo controlled clinical trial with controlled human malaria infections (CHMI) to evaluate safety, tolerability, pharmacokinetics, and protective efficacy of an anti-malaria human monoclonal antibody, MAM01, in healthy, malaria-naive adults\n          \n          \n          2023"},{"key":"B117","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12936-015-0817-x","article-title":"Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-na\u00efve volunteers: effect of injection volume and dose on infectivity rates","volume":"14","author":"G\u00f3mez-P\u00e9rez","year":"2015","journal-title":"Malaria J"},{"key":"B118","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12936-015-0628-0","article-title":"Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres","volume":"14","author":"Mordmuller","year":"2015","journal-title":"Malar J"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1990.43.441","article-title":"Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans","volume":"43","author":"Rickman","year":"1990","journal-title":"Am J Trop Med Hyg"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3201\/eid2912.230637","article-title":"Detection of anopheles stephensi mosquitoes by molecular surveillance, Kenya","volume":"29","author":"Ochomo","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2008.78.878","article-title":"Blood-stage challenge for malaria vaccine efficacy trials: A pilot study with discussion of safety and potential value","volume":"78","author":"Sanderson","year":"2008","journal-title":"Am J Trop Med Hygiene"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1086\/427243","article-title":"Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites","volume":"191","author":"Bejon","year":"2005","journal-title":"J Infect Diseases"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98012","article-title":"A controlled human malaria infection model enabling evaluation of transmission-blocking interventions","volume":"128","author":"Collins","year":"2018","journal-title":"J Clin Invest"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa157","article-title":"A randomized clinical trial to compare plasmodium falciparum gametocytemia and infectivity after blood-stage or mosquito bite\u2013induced controlled malaria infection","volume":"224","author":"Alkema","year":"2021","journal-title":"J Infect Diseases"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.08.073","article-title":"Transmission blocking malaria vaccines: Assays and candidates in clinical development","volume":"33","author":"Sauerwein","year":"2015","journal-title":"Vaccine"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.31549","article-title":"A randomized feasibility trial comparing four antimalarial drug regimens to induce Plasmodium falciparum gametocytemia in the controlled human malaria infection model","volume":"7","author":"Reuling","year":"2018","journal-title":"Elife"},{"key":"B127","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12936-025-05277-x","article-title":"Controlled human malaria infection: overview and potential application in the evaluation of transmission-blocking interventions in malaria-endemic areas","volume":"24","author":"Kessy","year":"2025","journal-title":"Malaria J"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01576-23","article-title":"A retrospective analysis of P. falciparum drug resistance markers detects an early (2016\/17) high prevalence of the k13 C469Y mutation in asymptomatic infections in Northern Uganda","volume":"68","author":"Ogwang","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-024-02174-4","article-title":"Protective efficacy and safety of radiation-attenuated and chemo-attenuated Plasmodium Falciparum sporozoite vaccines against controlled and natural malaria infection: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Abuelazm","year":"2024","journal-title":"Infection"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312775","article-title":"Subcutaneous administration of a monoclonal antibody to prevent malaria","volume":"390","author":"Kayentao","year":"2024","journal-title":"N Engl J Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.977472","article-title":"Five decades of clinical assessment of whole-sporozoite malaria vaccines","volume":"13","author":"Nunes-Cabaco","year":"2022","journal-title":"Front Immunol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01470-y","article-title":"Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"27","author":"Oneko","year":"2021","journal-title":"Nat Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/nature21060","article-title":"Sterile protection against human malaria by chemoattenuated PfSPZ vaccine","volume":"542","author":"Mordm\u00fcller","year":"2017","journal-title":"Nature"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03347-2","article-title":"Single immunization with genetically attenuated Pf\u0394mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial","volume":"31","author":"Roozen","year":"2025","journal-title":"Nat Med"},{"key":"B135","doi-asserted-by":"publisher","first-page":"112589","DOI":"10.1016\/j.isci.2025.112589","article-title":"Correlative humoral and cellular immunity to genetically attenuated malaria parasites in humans","volume":"28","author":"Colstrup","year":"2025","journal-title":"iScience"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.10.4421-4422.2005","article-title":"Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration","volume":"49","author":"Edstein","year":"2005","journal-title":"Antimicrobial Agents Chemother"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30420-1","article-title":"HRP-2 deletion: a hole in the ship of malaria elimination","volume":"18","author":"Verma","year":"2018","journal-title":"Lancet Infect Diseases"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2019.12.004","article-title":"HRP2: transforming malaria diagnosis, but with caveats","volume":"36","author":"Poti","year":"2020","journal-title":"Trends Parasitol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.19-0763","article-title":"Multiplex human malaria array: quantifying antigens for malaria rapid diagnostics","volume":"102","author":"Jang","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.21-0532","article-title":"Diagnostic characteristics of lactate dehydrogenase on a multiplex assay for malaria detection including the zoonotic parasite plasmodium knowlesi","volume":"106","author":"Barney","year":"2022","journal-title":"Am J Trop Med Hygiene"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91520-2","article-title":"Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick antigen-capture assay","volume":"343","author":"Beadle","year":"1994","journal-title":"Lancet"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.bmb.a074054","article-title":"Clinical, chemotherapeutic and immunological studies on induced malaria","volume":"8","author":"Covell","year":"1951","journal-title":"Br Med Bulletin"},{"key":"B143","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4269\/tropmed.1999.61-036","article-title":"A retrospective examination of sporozoite- and trophozoite-induced infections with plasmodium falciparum in patients previously infected with heterologous species of plasmodium: effect on development of parasitologic and clinical immunity","volume":"61","author":"Collins","year":"1999","journal-title":"Am Soc Trop Med Hygiene"},{"key":"B144","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1038\/s41467-024-49041-2","article-title":"Repeat controlled human Plasmodium falciparum infections delay bloodstream patency and reduce symptoms","volume":"15","author":"Ferrer","year":"2024","journal-title":"Nat Commun"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.984323","article-title":"Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: Safety and parasite growth dynamics","volume":"13","author":"Salkeld","year":"2022","journal-title":"Front Immunol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2021.1981864","article-title":"Multi-functional antibody profiling for malaria vaccine development and evaluation","volume":"20","author":"Opi","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.914598","article-title":"Innate immunity to malaria: The good, the bad and the unknown","volume":"13","author":"Pohl","year":"2022","journal-title":"Front Immunol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0209-5","article-title":"Antibodies against Plasmodium falciparum malaria at the molecular level","volume":"19","author":"Julien","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1038\/ni.f.205","article-title":"Immunity to malaria: more questions than answers","volume":"9","author":"Langhorne","year":"2008","journal-title":"Nat Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.83874.sa2","article-title":"The Dantu blood group prevents parasite growth in vivo: Evidence from a controlled human malaria infection study","volume":"12","author":"Kariuki","year":"2023","journal-title":"eLife"},{"key":"B151","volume-title":"A longitudinal survey of natural malaria infection in a group of West African adults\/by L","author":"Bruce-Chwatt","year":"1962"},{"key":"B152","first-page":"199","article-title":"The inoculation of semi-immune Africans with sporozoites of Laverania falcipara (Plasmodium falciparum) in Liberia","volume":"41","author":"Bray","year":"1962","journal-title":"Riv Malariol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"13303","DOI":"10.1038\/s41598-022-17725-8","article-title":"Immunological profiles associated with distinct parasitemic states in volunteers undergoing malaria challenge in Gabon","volume":"12","author":"Manurung","year":"2022","journal-title":"Sci Rep"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.immuni.2024.05.001","article-title":"Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge","volume":"57","author":"Nkumama","year":"2024","journal-title":"Immunity"},{"key":"B155","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1038\/s41467-022-31640-6","article-title":"Phagocytosis of Plasmodium falciparum ring-stage parasites predicts protection against malaria","volume":"13","author":"Musasia","year":"2022","journal-title":"Nat Commun"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn5993","article-title":"Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria","volume":"15","author":"Odera","year":"2023","journal-title":"Sci Transl Med"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02866","article-title":"KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization","volume":"9","author":"Kamuyu","year":"2018","journal-title":"Front Immunol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.894770","article-title":"Breadth of antibodies to plasmodium falciparum variant surface antigens is associated with immunity in a controlled human malaria infection study","volume":"13","author":"Kimingi","year":"2022","journal-title":"Front Immunol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/14760584.2023.2245890","article-title":"Sporozoite immunization: innovative translational science to support the fight against malaria","volume":"22","author":"Richie","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.793913","article-title":"Undertaking community engagement for a controlled human malaria infection study in Kenya: approaches and lessons learnt","volume":"10","author":"Mumba","year":"2022","journal-title":"Front Public Health"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040273","article-title":"Grand challenges in global health: community engagement in research in developing countries","volume":"4","author":"Tindana","year":"2007","journal-title":"PLoS Med"},{"key":"B162","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1186\/s13063-021-05455-7","article-title":"Understanding the benefits and burdens associated with a malaria human infection study in Kenya: experiences of study volunteers and other stakeholders","volume":"22","author":"Chi","year":"2021","journal-title":"Trials"},{"key":"B163","doi-asserted-by":"publisher","first-page":"8708","DOI":"10.1038\/s41598-023-35752-x","article-title":"Perceptions and acceptability of the controlled human malaria infection (CHMI) model in The Gambia: a qualitative study","volume":"13","author":"Dabira","year":"2023","journal-title":"Sci Rep"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.25259\/IJMR_985_2024","article-title":"Ethics & utility of controlled human infection studies (CHIS) in low- & middle-income countries","volume":"160","author":"Eberts","year":"2024","journal-title":"Indian J Med Res"},{"key":"B165","doi-asserted-by":"publisher","first-page":"19","DOI":"10.7196\/SAJBL.2023.v16i1.199","article-title":"Strengthening research ethics oversight in Africa: The Kenyan example","volume":"16","author":"Omutoko","year":"2023","journal-title":"South Afr J Bioethics Law"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1672945\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T05:33:02Z","timestamp":1758173582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1672945\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":165,"alternative-id":["10.3389\/fimmu.2025.1672945"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1672945","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"article-number":"1672945"}}